Chemistry:Navlimetostat

From HandWiki

Navlimetostat is an investigational new drug that is being evaluated by Mirati Therapeutics abd Bristol-Myers Squibb for the treatment of adenocarcinoma.[1] It is a PRMT5 protein inhibitor.[1][2][3]

References

  1. ↑ 1.0 1.1 "Navlimetostat - Bristol-Myers Squibb". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800064900. 
  2. ↑ "Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers". Journal of Medicinal Chemistry 65 (3): 1749–1766. February 2022. doi:10.1021/acs.jmedchem.1c01900. PMID 35041419. 
  3. ↑ "Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities". Journal of Biomedical Science 33 (1). April 2026. doi:10.1186/s12929-026-01240-3. PMID 41928257. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Navlimetostat&oldid=4582550"